Nicotine patches on PBS a welcome move 10 Dec 2010 0 comments The Federal government’s decision to include nicotine patches in the Pharmaceuticals Benefits Scheme has been welcomed by the Queensland Cancer Council.
Potential role of simvastatin in small cell lung cancer 10 Dec 2010 0 comments An exploratory phase 2 study has suggested that adding simvastatin to irinotecan/cisplatin chemotherapy may improve outcomes in patients with extensive small cell lung cancer.
Erlotinib receives TGA approval for lung cancer 19 Nov 2010 0 comments Patients with locally advanced or metastatic non-small cell lung cancer who have not progressed on first-line chemotherapy can now be prescribed erlotinib after being approved by the TGA.
Treatment of metastatic NSCLC 'justified' 1 Oct 2010 0 comments Radical treatment of thoracic tumours may be justified in some patients with non-small cell lung cancer who already have brain metastases at the time of diagnosis, oncologists have argued.
Early palliative care improves quality of life, survival 19 Aug 2010 0 comments Integrating palliative care early in the treatment of patients with advanced lung cancer can improve mood and quality of life and also extend survival, research shows.
Autoantibodies may diagnose early lung cancer 5 Aug 2010 0 comments A panel of six autoantibodies may provide a specific and reasonably sensitive early test for lung cancer, a multinational study has suggested.
Gene mutation testing needed in NSCLC 16 Jul 2010 0 comments Clinicians have called for EGFR gene mutation testing to become a routine part of non-small cell lung cancer diagnosis after the Therapeutic Goods Administration's approval of oral gefitinib.
Gefitinib effective first-line in EGFR-mutated NSCLC 25 Jun 2010 0 comments Gefitinib improves progression-free survival compared to carboplatin-paclitaxel when used first-line in patients with metastatic EGFR-mutated non-small-cell lung cancer, a new study has concluded.
Vandetanib plus docetaxel prolongs progression-free survival in NSCLC 8 Jun 2010 0 comments The addition of vandetanib to docetaxel prolongs progression-free survival in patients with previously treated advanced non-small-cell lung cancer an international study presented at the ASCO…
Sydney study explores reasons for lung cancer non-treatment 13 May 2010 0 comments A substantial number of lung cancer patients are not receiving the treatment recommended to them by multidisciplinary teams, a Sydney study has found.
